CD274 and head and neck squamous cell carcinoma: Clinically, some patients with PD-L1–negative HNSCC could still benefit from immunotherapy (42), while higher expression level of PD-L1 seems to be not correlated with better survival in longer-term follow-up of immunotherapy (43).